We Hate Your Drug. And That's a Good Thing.

Participants in a clinical trial didn't like Pain Therapeutics (Nasdaq: PTIE  ) and Pfizer's (NYSE: PFE  ) painkiller Remoxy as much as Purdue Pharma's OxyContin. But the duo didn't mind. In fact, they were trumpeting the results of the study.

You see, the participants in the study were drug abusers, and Remoxy is an abuse-deterrent formulation of the same active ingredient as OxyContin. Not liking to abuse the drug is kind of the point.

Remoxy uses DURECT's (Nasdaq: DRRX  ) technology to slowly release the pain drug that's encapsulated in a gel that makes it hard to get the active ingredient out all at once. Despite their best efforts, the study participants couldn't chew on the drug for more than 90 seconds because it tastes so bad. The drug abusers preferred the extended release OxyContin because they could be easily crushed to release all of the active compound at once.

Last week, the Food and Drug Administration said that all drugmakers -- from Pfizer and Johnson & Johnson (NYSE: JNJ  ) down to generic drugmakers Teva Pharmaceuticals (Nasdaq: TEVA  ) and Mylan (Nasdaq: MYL  ) -- that sell Long-Acting and Extended-Release Opioids had to establish a single comprehensive plan to instruct doctors about how to make sure the patients that need the drugs get them but that they stay out of the hands of drug abusers.

Remoxy was originally up for review by the FDA in 2008 when the agency said it wanted more information about the abuse-deterrent part of the drug. We'll know soon enough whether Remoxy can get past the agency when the FDA makes a new decision on or around June 23. Considering the agency's new stance on prescription drug abuse and the new data that Pain and Pfizer have in hand, Remoxy should have an easier time getting liked by the FDA.

Interested in up and coming technology? Click here to get the Fool's free report, The Only Stock You Need To Profit From the NEW Technology Revolution.

Johnson & Johnson and Pfizer are Motley Fool Inside Value picks. Teva Pharmaceutical Industries is a Motley Fool Global Gains selection. Johnson & Johnson is a Motley Fool Income Investor recommendation. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of Johnson & Johnson, and Teva Pharmaceutical Industries. Alpha Newsletter Account, LLC owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1482085, ~/Articles/ArticleHandler.aspx, 9/20/2014 8:12:35 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement